Pharmaceutical company
Appears in 30 stories · Last updated Nov 11, 2026
Must update Mounjaro and Zepbound labels
On November 9, the US Food and Drug Administration told every maker of a GLP-1 drug to add a warning about a rare eye condition to its label. The condition is nonarteritic anterior ischemic optic neuropathy, or NAION: a loss of blood flow to the optic nerve that can permanently blind one eye, usually without pain.
Updated 12 hours ago
Expanding its obesity drugs into telehealth
A patient on Hims & Hers can now get a prescription for Eli Lilly's obesity drugs and have them shipped to their door without leaving the app. Before Nov. 6, Lilly's Zepbound and Foundayo were only reachable through Lilly's own cash-pay site, LillyDirect.
Updated 2 days ago
Defendant; facing a Nov. 26 deadline to drop its Missouri data demand
Five Massachusetts hospitals sued Eli Lilly in federal court in Boston on Oct. 27, saying the drugmaker cut off discounted prices to force them to hand over patient claims data. The hospitals are Massachusetts General, Brigham and Women's, Salem, and two UMass Memorial facilities.
Updated 7 days ago
FDA approved its once-weekly insulin Onswik (efsitora alfa) for adults with type 2 diabetes on September 24, 2026; the UK authorised it October 13, and US pens are due in the coming months
The FDA approved Awiqli on March 26, 2026, making it the first once-weekly basal insulin for adults with type 2 diabetes. It replaces 365 daily basal shots a year with 52.
Updated Oct 27
Developer of olomorasib; acquired Loxo Oncology in 2019
KRAS G12C-mutant non-small cell lung cancer has no approved first-line targeted therapy. Standard care is immunotherapy with or without chemotherapy, and most patients never reach second-line treatment, so the first choice carries a lot of weight.
Updated Oct 26
Developer of sofetabart mipitecan (Sofe-M)
Sofetabart mipitecan (Sofe-M) plus bevacizumab shrank tumors in 23 of 29 evaluable platinum-sensitive ovarian cancer patients, a 79.3% confirmed response rate. Every patient in the Phase 1 cohort had a response or stable disease, and the rate held in patients who had already taken a PARP inhibitor.
Presented one-year SHINE-2 data at UEG Week 2026; preparing regulatory submissions for a pediatric ulcerative colitis label
Half of the children who responded to Eli Lilly's Omvoh stayed in remission at one year, the first one-year Phase 3 result for an IL-23 inhibitor in pediatric ulcerative colitis. Among 52 week-12 responders aged 6 to 17, half were in clinical remission at week 52 and half were steroid-free and surgery-free, Lilly reported on October 19 at UEG Week 2026.
Updated Oct 25
Manufacturer and marketer of Jaypirca (pirtobrutinib)
The FDA on October 2 cleared Eli Lilly's Jaypirca for newly diagnosed chronic lymphocytic leukemia, the first non-covalent BTK inhibitor approved as initial therapy. The label covers adults without a known 17p deletion, roughly 92% to 95% of new cases.
Updated Oct 20
Sponsor of TRIUMPH-1 and developer of retatrutide
Eli Lilly's obesity drug retatrutide met its goals in two late-stage trials published in late September. The 12 mg dose produced 30.3% average weight loss over 104 weeks in adults with obesity, per Lilly's topline (the NEJM paper's primary 80-week endpoint was 25.0%), a level once seen mainly after bariatric surgery. In 1,152 adults with type 2 diabetes, the same dose cut weight 18.8% at 80 weeks, and 79% reached an HbA1c of 6.5% or lower.
Updated Oct 18
Developer of Foundayo (orforglipron); FDA approved the drug for obesity in April 2026; CHMP recommended EU approval for obesity and type 2 diabetes on October 16, 2026; type 2 diabetes FDA submission planned for end of Q2 2026
Millions with type 2 diabetes manage blood sugar with daily injections. Lilly's Foundayo is a pill that could replace them, and in its largest trial it matched insulin on heart safety while cutting weight and blood sugar more.
Markets orforglipron, the first approved oral small-molecule GLP-1
Injectable GLP-1 drugs like Ozempic need needles, and Rybelsus, the first oral version, must be taken on an empty stomach. Lilly's orforglipron, an oral small molecule approved in 2026, avoids that rule. Hengrui's safiglipron is a once-daily pill that also works with food.
Advancing EloraTZP to Phase 3 trials
Adults with obesity and type 2 diabetes who took Eli Lilly's experimental EloraTZP lost an average of 23.3% of their body weight over 48 weeks — well beyond the 14.8% lost by those on tirzepatide alone, the drug sold as Zepbound. The combination pairs tirzepatide, a dual GIP and GLP-1 receptor agonist, with eloralintide, a selective amylin receptor agonist, engaging three appetite-regulating hormone pathways at once.
As of October 2026: Developing AK-OTOF gene therapy through acquired subsidiary
A single injection into the inner ear can now restore hearing in children born deaf. In April 2026 the FDA approved Otarmeni, the first gene therapy for inherited hearing loss, after about 80% of 24 trial participants gained measurable hearing and 42% could pick up whispers.
Updated Oct 3
As of September 2026: Competitor; markets tirzepatide as Mounjaro and Zepbound
Roche's experimental once-weekly diabetes injectable cut blood sugar and body weight in a 48-week phase 2 trial announced September 22. Patients on the highest 24 mg dose saw HbA1c drop 2.65 percentage points and weight fall 15.5%.
Updated Sep 22
As of September 2026: Acquiring Centessa's orexin pipeline for up to $7.8B
Alkermes presented its orexin agonist as an ADHD treatment on September 21, the first time the new drug class has moved into a mainstream psychiatric market. The company calls the program a potential 'company changer.'
Updated Sep 21
As of September 2026: Acquirer; integrating Merida into its immunology pipeline
Eli Lilly agreed to buy Merida Biosciences for up to $2.875 billion. The deal adds a platform that destroys the specific antibodies driving autoimmune disease instead of broadly suppressing the immune system. Merida's lead drug, MER511, is in early human testing for Graves' disease and thyroid eye disease.
Updated Sep 1
As of August 2026: Maker of tirzepatide (Mounjaro, Zepbound); FDA approved Mounjaro for cardiovascular risk reduction in August 2026
The FDA approved tirzepatide (Mounjaro) on August 28 to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes at high risk. The decision rests on SURPASS-CVOT, a 13,000-patient trial that found tirzepatide matched an older GLP-1 medicine, dulaglutide (Trulicity), on major heart events, with an estimated 8% lower rate.
Updated Aug 29
As of August 2026: Partner in diagnostic development and maker of Kisunla
Alzheimer's diagnosis used to require a $5,000 brain scan or a painful spinal tap. As of August 2026, the FDA has cleared four blood tests for the disease, from Roche's Elecsys pTau217 to C2N's PrecivityAD2, approved for adults as young as 40.
Updated Aug 25
As of July 2026: Acquirer
Eli Lilly agreed to buy AtaiBeckley for $6.75 a share in cash, about $2.8 billion, with up to $1 billion more if two drugs hit development targets. The purchase pulls one of the world's largest drugmakers into psychedelic medicine.
Updated Jul 16
As of May 2026: Surpassing Novo Nordisk in GLP-1 market share with expanding product line
Kailera Therapeutics just pulled off the largest biotech initial public offering in history, raising $625 million and watching its shares surge 62.5% on the first day of trading. The company, founded less than two years ago with drugs licensed from a Chinese pharmaceutical firm, is now valued at roughly $3.5 billion — without a single approved product. That a startup built entirely around next-generation obesity drugs can command this kind of investor enthusiasm tells you where the pharmaceutical industry's center of gravity has shifted.
Updated May 31
As of May 2026: Constructing $9B+ manufacturing campus at LEAP
Indiana committed over $23 billion in private investment to a 9,500-acre industrial district in Boone County farmland before solving a basic problem: where the water would come from. The state is advancing a $560 million plan to pipe up to 25 million gallons per day from Indianapolis. The water would supply Eli Lilly's $9 billion pharmaceutical campus and Meta's $10 billion data center complex, despite objections from Indianapolis lawmakers, environmental groups, and hundreds of property owners along the pipeline route.
As of May 2026: Launched Foundayo, expanding oral GLP-1 market
For two years, the most effective weight-loss drugs on the market required a weekly injection, but that barrier is now falling. Eli Lilly began shipping Foundayo on April 6, 2026 — just five days after FDA approval in a record 50-day review — making it the first oral GLP-1 pill with no food or water restrictions. At $149/month (or $25 with insurance), it's 85% cheaper than injectables.
Updated May 30
As of May 2026: Manufacturer of Mounjaro and Zepbound; Novo Nordisk's primary GLP-1 competitor
More than 30 million Americans now take GLP-1 receptor agonist drugs like Ozempic and Wegovy to lose weight. A persistent concern has dogged the medications since their rise: that they burn through muscle along with fat, leaving patients weaker even as they get thinner.
As of May 2026: Second-largest GLP-1 franchise; advancing oral formulation
The biggest knock against blockbuster weight-loss drugs like semaglutide is that up to 40% of weight lost is lean tissue (muscle and bone), not fat. New therapies entering trials target genes to spare muscle.
As of May 2026: Launches first non-fasting oral GLP-1 for obesity, intensifying competition in weight loss market
For the first time, patients with acquired hypothalamic obesity have an FDA-approved treatment. On March 19, 2026, the FDA approved Imcivree (setmelanotide), which targets this rare condition affecting roughly 10,000 Americans whose hypothalamic damage from brain tumor surgery makes diet and exercise ineffective.
As of May 2026: Actively pursuing GLP-1 addiction trials
Drugs designed to control blood sugar and shrink waistlines may also quiet the cravings that drive addiction. A March 4 BMJ study of more than 600,000 U.S. veterans found GLP-1 users were 14 percent less likely to develop a new substance use disorder.
As of May 2026: Maker of tirzepatide; chief GLP-1 competitor
Patients on Ozempic and Wegovy typically lose about 15% of their body weight, then stall around 14 months in. On May 25, NIH researchers in Nature Metabolism reported what may be happening inside the brain to cause that stall, and a way to keep the drug working longer.
Updated May 25
As of May 2026: Maker of tirzepatide (Mounjaro, Zepbound), included in the GLP-1 cohort
A study of more than 12,000 patients found that those taking GLP-1 weight-loss drugs were 38% to 50% less likely to progress to stage IV cancer in four obesity-linked cancers. Cleveland Clinic led the study. Researchers compared GLP-1 users — on drugs like Ozempic, Wegovy, and Mounjaro — against patients taking older diabetes pills.
Updated May 24
As of May 2026: Reduced insulin prices by 70% in 2023
On January 1, 2026, nonprofit Civica Rx launched insulin glargine pens at $55 a box; California debuted its CalRx-branded insulin the same day at the same price. Both undercut branded products by up to 90%: no insurance forms, no rebates, no hidden markups, just one transparent price for anyone, in a market three pharmaceutical giants control with a 90% share.
Updated May 19
As of May 2026: Negotiating partner in BALANCE model
Medicare has been banned from covering weight loss drugs since 2003. CMS launched BALANCE in December 2025, a voluntary model offering $50-per-month Ozempic and Wegovy access for 10% of Medicare enrollees starting July 2026.
Updated May 16
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
